Intellia Therapeutics Inc (NTLA) concluded trading on Thursday at a closing price of $9.90, with 4.49 million shares of worth about $44.41 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -54.21% during that period and on March 06, 2025 the price saw a gain of about 5.71%. Currently the company’s common shares owned by public are about 102.03M shares, out of which, 97.77M shares are available for trading.
Stock saw a price change of -8.84% in past 5 days and over the past one month there was a price change of 2.91%. Year-to-date (YTD), NTLA shares are showing a performance of -15.09% which decreased to -69.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.30 but also hit the highest price of $32.00 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 3.06 million. The stock is currently trading -5.07% below its 20-day simple moving average (SMA20), while that difference is down -7.77% for SMA50 and it goes to -45.37% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 102.03M outstanding shares and institutions hold larger chunk of about 90.19% of that.
The stock has a current market capitalization of $1.02B and its 3Y-monthly beta is at 2.15. It has posted earnings per share of -$5.25 in the same period. It has Quick Ratio of 5.77 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 10.79% while standing at 8.62% over the month.
Stock’s fiscal year EPS is expected to rise by 10.40% while it is estimated to increase by 5.29% in next year. EPS is likely to grow at an annualized rate of 25.47% for next 5-years, compared to annual growth of -20.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on March 05, 2025 offering a Buy rating for the stock and assigned a target price of $30 to it. Coverage by JP Morgan stated Intellia Therapeutics Inc (NTLA) stock as a Neutral in their note to investors on February 28, 2025, suggesting a price target of $13 for the stock. On February 28, 2025, Goldman Downgrade their recommendations, while on January 27, 2025, Morgan Stanley Downgrade their ratings for the stock with a price target of $11. Stock get a Neutral rating from Goldman on February 23, 2024.
